Repros Therapeutics (RPRX) Suspends At-The-Market Common Offering; Updates on Androxal Type II Diabetes Study
Tweet Send to a Friend
Repros Therapeutics Inc. (Nasdaq: RPRX) today announced it has suspended its at-the-market offering of Company securities. On February 18, 2010 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
